Benzinga  Mar 1  Comment 
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) today announced the voluntary nationwide recall of one lot of Fluconazole Injection, USP, (in 0.9% Sodium Chloride) 200mg per 100mL flexible container bag (NDC 25021-113-82) Lot 40608 manufactured by ACS...
Reuters  Jan 13  Comment 
Sagent Pharmaceuticals Inc, a U.S. generic life sciences company focusing on injectable drugs, is considering a sale of the company as part of an exploration of strategic...


Sagent Pharmaceuticals (NASDAQ:SGNT) is a pharmaceutical company which sells injectable drugs. Sagent focuses on the generic injectable market in particular. In addition to selling and marking the drugs, Sagent also develops them and brings them through the Food and Drug Administration (FDA) approval process. With its first drug approved in 2007, Sagent has had an increasing number of drugs approved from then until is IPO.[1]

Sagnet focuses on developing generic drugs and therefore uses the Abbreviated New Drug Application (ANDA) process with the FDA. This process consists of the approval of an existing drug but simply in its generic form. Because they are the generic form of an existing drug, the approval process generally does not require the preclinical (animal) and clinical (human) trials. Instead, they must demonstrate similarity to the existing drug. By going through the ANDA process, the rate of approval is far greater and the intensity of research is lower for Sagent. However, the company may only apply for an ANDA when the patent on the non-generic version has expired.[2]

The company's initial public offering of stock on the NASDAQ occurred on April 19, 2011. The company offered 5.8M shares each for $16. This was at the high end of the initial price range of $14-$16. This brought the total deal size to $92M. The lead underwriters of the deal were Morgan Stanley (MS), Bank of America (BAC), and Jefferies Group (JEF).[3]

For the full year 2010, Sagent reported a total revenue of $74M. This was a substantial increase over the total revenue of $29M in 2009. However, the company reported a net loss for 2010 of $24.5M.[4]


  1. SGNT S-1/A 2011 PROSPECTUS SUMMARY "Overview" pg 1
  2. SGNT S-1/A 2011 PROSPECTUS SUMMARY "Our Competitive Strengths" pg 3-5
  3. Renaissance Capital - IPO Home "Sagent Pharmaceuticals prices upsized IPO at $16, high end of the range" 20 April 2011
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki